pomalidomide + zanubrutinib

Pomalidomide + zanubrutinib is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action. Pomalidomide is an immunomodulatory agent and thalidomide derivative that exerts anti-angiogenic, anti-proliferative, and immunomodulatory effects primarily through modulation of the cereblon E3 ubiquitin ligase complex, leading to degradation of specific transcription factors involved in tumor cell survival. Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds covalently to the Cys481 residue in BTK's ATP-binding pocket, thereby blocking B-cell receptor signaling and inhibiting proliferation and survival of malignant B cells. This combination has been explored for use in relapsed or refractory hematologic malignancies such as multiple myeloma and lymphoma[1][6][10]. Both agents are orally administered small molecules.